Search results
Added:
4 weeks ago
Added:
1 year ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical…
View more
Added:
2 years ago
ERA 23 - In this short video from ERA 23, we are joined by Dr Navdeep Tangri (Max Rady College of Medicine, Manitoba, CA) to discuss the findings from the REVEAL-CKD Trial.
REVEAL-CKD is a retrospective, multinational, non-interventional, observational study which aimed to investigate the prevalence and consequences of undiagnosed chronic kidney disease (CKD) in a cohort of 670000 participants.
…
View more
Added:
12 months ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of…
View more
Added:
5 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of…
View more
Added:
1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical…
View more
Added:
5 months ago
ESC HF 25 - FIVE-STAR primary outcome is neutral, though finerenone was shown to significantly reduce UACR rates with a 29% greater reduction compared to placebo.We are joined by Dr Atsushi Tanaka (Saga University, Saga, JP) to discuss the findings from FIVE-STAR, a randomized trial investigating the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2…
View more
Added:
1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an…
View more
Added:
3 months ago
Added:
5 months ago
ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status.ProfWilliam Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes,…
View more